Vesara Ardhe Gatera, Rizky Abdulah, Ida Musfiroh, Raden Tina Dewi Judistiani, Budi Setiabudiawan
{"title":"维生素D作为呼吸窘迫综合征危险因素的最新进展。","authors":"Vesara Ardhe Gatera, Rizky Abdulah, Ida Musfiroh, Raden Tina Dewi Judistiani, Budi Setiabudiawan","doi":"10.1155/2018/8494816","DOIUrl":null,"url":null,"abstract":"<p><p>To update the guidelines regarding vitamin D status in respiratory distress syndrome, we reviewed recent human and animal studies on the benefits of vitamin D in respiratory distress. We searched PubMed and ProQuest for studies on the use of vitamin D from 2009 to 2017. The common parameters in these studies included the use of lung tissue, phospholipids, blood, and plasma to assess the effects of vitamin D on respiratory syndrome. The metabolized form of vitamin D used in these studies was 1,25(OH)<sub>2</sub>D<sub>3</sub> in animal studies and 25(OH)D in human studies. Vitamin D supplementation decreases the risk of respiratory distress syndrome, improves the quality of life, and is relatively effective and safe for preterm neonates as well as during lung maturation. However, although vitamin D supplementation may offer benefits for respiratory distress syndrome, the optimal dosing strategies for specific types of risk factors in the lungs must be clarified to confirm the therapeutic efficacy.</p>","PeriodicalId":7389,"journal":{"name":"Advances in Pharmacological Sciences","volume":"2018 ","pages":"8494816"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/8494816","citationCount":"17","resultStr":"{\"title\":\"Updates on the Status of Vitamin D as a Risk Factor for Respiratory Distress Syndrome.\",\"authors\":\"Vesara Ardhe Gatera, Rizky Abdulah, Ida Musfiroh, Raden Tina Dewi Judistiani, Budi Setiabudiawan\",\"doi\":\"10.1155/2018/8494816\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>To update the guidelines regarding vitamin D status in respiratory distress syndrome, we reviewed recent human and animal studies on the benefits of vitamin D in respiratory distress. We searched PubMed and ProQuest for studies on the use of vitamin D from 2009 to 2017. The common parameters in these studies included the use of lung tissue, phospholipids, blood, and plasma to assess the effects of vitamin D on respiratory syndrome. The metabolized form of vitamin D used in these studies was 1,25(OH)<sub>2</sub>D<sub>3</sub> in animal studies and 25(OH)D in human studies. Vitamin D supplementation decreases the risk of respiratory distress syndrome, improves the quality of life, and is relatively effective and safe for preterm neonates as well as during lung maturation. However, although vitamin D supplementation may offer benefits for respiratory distress syndrome, the optimal dosing strategies for specific types of risk factors in the lungs must be clarified to confirm the therapeutic efficacy.</p>\",\"PeriodicalId\":7389,\"journal\":{\"name\":\"Advances in Pharmacological Sciences\",\"volume\":\"2018 \",\"pages\":\"8494816\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2018/8494816\",\"citationCount\":\"17\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Pharmacological Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2018/8494816\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Pharmacological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2018/8494816","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Updates on the Status of Vitamin D as a Risk Factor for Respiratory Distress Syndrome.
To update the guidelines regarding vitamin D status in respiratory distress syndrome, we reviewed recent human and animal studies on the benefits of vitamin D in respiratory distress. We searched PubMed and ProQuest for studies on the use of vitamin D from 2009 to 2017. The common parameters in these studies included the use of lung tissue, phospholipids, blood, and plasma to assess the effects of vitamin D on respiratory syndrome. The metabolized form of vitamin D used in these studies was 1,25(OH)2D3 in animal studies and 25(OH)D in human studies. Vitamin D supplementation decreases the risk of respiratory distress syndrome, improves the quality of life, and is relatively effective and safe for preterm neonates as well as during lung maturation. However, although vitamin D supplementation may offer benefits for respiratory distress syndrome, the optimal dosing strategies for specific types of risk factors in the lungs must be clarified to confirm the therapeutic efficacy.
期刊介绍:
Advances in Pharmacological and Pharmaceutical Sciences is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of experimental and clinical pharmacology, pharmaceutics, medicinal chemistry and drug delivery. Topics covered by the journal include, but are not limited to: -Biochemical pharmacology, drug mechanism of action, pharmacodynamics, pharmacogenetics, pharmacokinetics, and toxicology. -The design and preparation of new drugs, and their safety and efficacy in humans, including descriptions of drug dosage forms. -All areas of medicinal chemistry, such as drug discovery, design and synthesis. -Basic biology of drug and gene delivery through to application and development of these principles, through therapeutic delivery and targeting. Areas covered include bioavailability, controlled release, microcapsules, novel drug delivery systems, personalized drug delivery, and techniques for passing biological barriers.